Diagnostic Consultative Centre Ascendent OOD
Verified site
Sofia, Bulgaria
Rare diseases
Investigational molecules
Locations
A plain-language summary of the goals, design and what participants do
The study examines a medicine called Cladribine, which is used to treat multiple sclerosis, a disease where the immune system mistakenly attacks the protective coating of nerve fibers. Two tablet forms containing the same amount of the drug are being compared: the brand name Mavenclad® and a test version of the same medication. The purpose is to assess whether the test tablet shows bioequivalence with the brand tablet, meaning it behaves the same way in the body.
Healthy adult volunteers will receive a single dose of each tablet on separate visits, with a gap of at least one month between doses, while fasting (no food). After each dose, blood samples will be collected to measure how much of the drug enters the bloodstream and how quickly it reaches its highest level. These measurements are referred to as AUC (total exposure) and Cmax (maximum concentration), and the time taken to reach the maximum level is called tmax. The study will compare these values between the two tablets to determine if they are equivalent.
The trial runs in 4 steps – from screening to follow-up. Each step says what happens and what the team monitors.
9 criteria
38 criteria
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
All sites with verified contact details – recruitment status may not be available; ask directly
Sofia, Bulgaria
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
Not recruitingJoining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
is a commercially available tablet that contains the medicine cladribine. In this study it is used as the reference product, meaning the researchers compare the new tablet to this known version to see if they behave the same way in the body. The tablet is taken by mouth on an empty stomach.
is the test tablet being evaluated in the trial. It also contains the same active ingredient, cladribine, but it is a new formulation that the investigators want to check for similarity to the marketed product. Like the reference tablet, it is swallowed whole and taken while fasting.
Mavenclad is taken as a 10 mg oral tablet that is swallowed with water. It is an approved medicine used to treat adults with highly active relapsing multiple sclerosis and is widely described in medical literature. The drug works by acting as a purine‑like molecule that enters immune cells and interferes with DNA building, which reduces the number of cells that cause inflammation. It belongs to the class of immunosuppressant antimetabolites and is considered a disease‑modifying therapy for MS.
The test product is also a 10 mg oral tablet taken by mouth with water. Cladribine is the same active ingredient as Mavenclad and is approved for the same MS indication, with many studies published on its safety and effectiveness. It works by mimicking a natural building block of DNA, entering certain immune cells and disrupting their ability to multiply, thereby lowering the immune attack on the nervous system. It is classified as an immunosuppressive antimetabolite used as a disease‑modifying treatment for multiple sclerosis.
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?
Tell us about your condition – we search every trial in Europe and connect you with the right site.